Fate Therapeutics, Inc. Stock price
Is Fate Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Fate Therapeutics, Inc. Stock Analysis
Analyst Opinions
18 Analysts have issued a Fate Therapeutics, Inc. forecast:
Analyst Opinions
18 Analysts have issued a Fate Therapeutics, Inc. forecast:
Don't miss a Thing! We will send you all news about Fate Therapeutics, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fate Therapeutics, Inc. Stock News
Company Profile
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Dr. Valamehr |
| Employees | 161 |
| Founded | 2007 |
| Website | fatetherapeutics.com |


